The global hyperhidrosis treatment market was valued at $575.3 million in 2021, and is estimated to reach $950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.
A person with hyperhidrosis experiences excessive and unpredictable sweating. When cool or when they are at rest, people with hyperhidrosis may nevertheless perspire. A person’s body's sweat glands overreact in hyperhidrosis. Excessive sweating can occasionally be brought on by a health issue or emotion (such as anxiety). Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is unidentified and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. The impact of hyperhidrosis symptoms on life can vary greatly in terms of their severity.
The major factors that drive the growth of the hyperhidrosis treatment market are rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of the hyperhidrosis treatment market. In addition, upsurge in utilization of topical treatments is a key trend of the market, which is expected to fuel the market growth during the forecast period. Significant surge in the incidence of hyperhidrosis is one leading factor for the growth of the market. Estimates suggest between 2% and 5% of people in the U. S. have hyperhidrosis Thus, such high number of cases are expected to boost the hyperhidrosis treatment procedures.
In addition, rise in product launch drives the market growth, for instance, in June 2022, Dr August Wolff GmbH & Co. Kg Drugs presented the new drug Axhidrox. It is topical treatment for severe primary axillary hyperhidrosis in adults. However, lack of awareness about treatment scenario is expected to hinder the growth of the market. Conversely, increasing consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.
The hyperhidrosis treatment market is segmented on the basis of type, treatment, age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. By treatment, it is divided into botulinum toxin injection, topical treatment, and oral medication. Oral medication is further bifurcated into anticholinergics and others. By age, it is classified into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd, Brickbell Biotech, Inc, Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.
A person with hyperhidrosis experiences excessive and unpredictable sweating. When cool or when they are at rest, people with hyperhidrosis may nevertheless perspire. A person’s body's sweat glands overreact in hyperhidrosis. Excessive sweating can occasionally be brought on by a health issue or emotion (such as anxiety). Controlling the symptoms of hyperhidrosis can be a constant struggle for many people. Hyperhidrosis patients seem to have excessively active sweat glands. Uncontrollable sweating can cause severe physical and emotional distress. The cause of hyperhidrosis is unidentified and it is generally believed to be the result of a disturbance with the portion of the nervous system that regulates sweating. The impact of hyperhidrosis symptoms on life can vary greatly in terms of their severity.
The major factors that drive the growth of the hyperhidrosis treatment market are rise in incidence of hyperhidrosis and surge in product launch & product approval are the factors attributed to the growth of the hyperhidrosis treatment market. In addition, upsurge in utilization of topical treatments is a key trend of the market, which is expected to fuel the market growth during the forecast period. Significant surge in the incidence of hyperhidrosis is one leading factor for the growth of the market. Estimates suggest between 2% and 5% of people in the U. S. have hyperhidrosis Thus, such high number of cases are expected to boost the hyperhidrosis treatment procedures.
In addition, rise in product launch drives the market growth, for instance, in June 2022, Dr August Wolff GmbH & Co. Kg Drugs presented the new drug Axhidrox. It is topical treatment for severe primary axillary hyperhidrosis in adults. However, lack of awareness about treatment scenario is expected to hinder the growth of the market. Conversely, increasing consumer demands in developing countries is expected to provide a great opportunity for the investors to invest in the market.
The hyperhidrosis treatment market is segmented on the basis of type, treatment, age, and region. On the basis of type, the market is categorized into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. By treatment, it is divided into botulinum toxin injection, topical treatment, and oral medication. Oral medication is further bifurcated into anticholinergics and others. By age, it is classified into below 50 years and above 50 years. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).
The major players profiled in the report are AbbVie Inc, Avanor Healthcare Ltd, Brickbell Biotech, Inc, Dr August Wolff GmbH & Co. Kg Drugs, Dr. Reddy's Laboratories Ltd, Eirion Therapeutics, Inc, Eli Lilly and Company, Hugel, Inc., Kaken Pharmaceutical Co., Ltd, Intas Pharmaceuticals Ltd, Roivant Sciences Ltd., and Theravida, Inc.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hyperhidrosis treatment market analysis from 2021 to 2031 to identify the prevailing hyperhidrosis treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the hyperhidrosis treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global hyperhidrosis treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Axillary hyperhidrosis
- Palmar hyperhidrosis
- Plantar hyperhidrosis
- Others
By Treatment
- Botulinum toxin injections
- Topical treatment
- Oral medication
- Type
- Anticholinergics
- Others
By Age
- Below 50 years
- Above 50 years
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
Key Market Players
- AbbVie Inc.
- Avanor Healthcare Ltd
- Brickbell Biotech, Inc
- Dr August Wolff Gmbh & Co. Kg Drugs
- Eirion Therapeutics, Inc
- Eli Lilly and Company
- Hugel, Inc
- Kaken Pharmaceutical Co., Ltd.
- Roivant Sciences Ltd.
- Theravida, Inc
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
3.7. Patent Landscape
CHAPTER 4: HYPERHIDROSIS TREATMENT MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Axillary hyperhidrosis
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Palmar hyperhidrosis
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Plantar hyperhidrosis
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Others
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: HYPERHIDROSIS TREATMENT MARKET, BY TREATMENT
5.1 Overview
5.1.1 Market size and forecast
5.2 Botulinum toxin injections
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Topical treatment
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Oral medication
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.4.4 Oral medication Hyperhidrosis Treatment Market by Type
5.4.4.1 Anticholinergics Market size and forecast, by region
5.4.4.2 Others Market size and forecast, by region
CHAPTER 6: HYPERHIDROSIS TREATMENT MARKET, BY AGE
6.1 Overview
6.1.1 Market size and forecast
6.2 Below 50 years
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Above 50 years
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: HYPERHIDROSIS TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Treatment
7.2.3.1 North America Oral medication Hyperhidrosis Treatment Market by Type
7.2.4 North America Market size and forecast, by Age
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Treatment
7.2.5.1.3 Market size and forecast, by Age
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Treatment
7.2.5.2.3 Market size and forecast, by Age
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Treatment
7.2.5.3.3 Market size and forecast, by Age
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Treatment
7.3.3.1 Europe Oral medication Hyperhidrosis Treatment Market by Type
7.3.4 Europe Market size and forecast, by Age
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Treatment
7.3.5.1.3 Market size and forecast, by Age
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Treatment
7.3.5.2.3 Market size and forecast, by Age
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Treatment
7.3.5.3.3 Market size and forecast, by Age
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Treatment
7.3.5.4.3 Market size and forecast, by Age
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Treatment
7.3.5.5.3 Market size and forecast, by Age
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Treatment
7.3.5.6.3 Market size and forecast, by Age
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Treatment
7.4.3.1 Asia-Pacific Oral medication Hyperhidrosis Treatment Market by Type
7.4.4 Asia-Pacific Market size and forecast, by Age
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Treatment
7.4.5.1.3 Market size and forecast, by Age
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Treatment
7.4.5.2.3 Market size and forecast, by Age
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Treatment
7.4.5.3.3 Market size and forecast, by Age
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Treatment
7.4.5.4.3 Market size and forecast, by Age
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Treatment
7.4.5.5.3 Market size and forecast, by Age
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Treatment
7.4.5.6.3 Market size and forecast, by Age
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Treatment
7.5.3.1 LAMEA Oral medication Hyperhidrosis Treatment Market by Type
7.5.4 LAMEA Market size and forecast, by Age
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Treatment
7.5.5.1.3 Market size and forecast, by Age
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Treatment
7.5.5.2.3 Market size and forecast, by Age
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Treatment
7.5.5.3.3 Market size and forecast, by Age
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Treatment
7.5.5.4.3 Market size and forecast, by Age
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Players
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 AbbVie Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Avanor Healthcare Ltd
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Brickbell Biotech, Inc
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Dr August Wolff Gmbh & Co. Kg Drugs
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eirion Therapeutics, Inc
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Eli Lilly and Company
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Hugel, Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Kaken Pharmaceutical Co., Ltd.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Roivant Sciences Ltd.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Theravida, Inc
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
9.11 Dr. Reddy's Laboratories Ltd.
9.11.1 Company overview
9.11.2 Company snapshot
9.11.3 Operating business segments
9.11.4 Product portfolio
9.11.5 Business performance
9.11.6 Key strategic moves and developments
9.12 Intas Pharmaceuticals Ltd
9.12.1 Company overview
9.12.2 Company snapshot
9.12.3 Operating business segments
9.12.4 Product portfolio
9.12.5 Business performance
9.12.6 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Hyperhidrosis Treatment Market,' the hyperhidrosis treatment market was valued at $575.32 million in 2021, and is estimated to reach $950.7 million by 2031, growing at a CAGR of 5.1% from 2022 to 2031.A disorder called hyperhidrosis disorder causes excessive sweating. This sweating can occur in unusual situations, such as in cooler weather, or without any trigger at all. Menopause or hyperthyroidism are two medical problems that can contribute to it. Hyperhidrosis can be uncomfortable. However, several treatment options can provide some relief. Sweating is a normal reaction to a variety of situations, including hot weather, strenuous exertion, stress, and emotions of fear or rage. An individual sweats more than normal and for no apparent cause in hyperhidrosis
Rise in patient population suffering from hyperhidrosis is the major factor that drives the hyperhidrosis treatment market growth. Many key market players have invested on R&D activities to launch and innovate new product for the treatment of hyperhidrosis, which propels the market growth. Furthermore, innovations, development of advanced technologies, key strategies adopted by the major market players, and increasing demand for topical treatment are the upcoming hyperhidrosis treatment market trends. However, less awareness among people about the treatment is expected to impede the market growth. Conversely, increase in demand in developing countries is a lucrative opportunity for the growth of the hyperhidrosis treatment market during the forecast period. .By type, the market is segmented into axillary hyperhidrosis palmar hyperhidrosis, plantar hyperhidrosis, and others. The axillary hyperhidrosis segment generated maximum revenue in 2021, and is anticipated to witness highest CAGR during the forecast period, owing to high incidence of axillary hyperhidrosis and wide availability of its treatment.
Depending on treatment, the market is divided into botulinum toxin injection, topical treatment, and oral medication. The topical treatment segment dominated the hyperhidrosis treatment market size in 2021, and is expected to witness highest CAGR during the forecast period owing to rapid effects and cost-effective treatment. By age, the market is bifurcated into below 50 years and above 50 years. The below 50 years segment dominated the market in 2021, and is expected to witness highest CAGR during the forecast period owing to incidence of disease in more in below 50-year age group.
North America accounted for a majority of the global hyperhidrosis treatment market share in 2021, and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in hyperhidrosis treatment , high incidence of disease, and presence of key players in the region. However, Asia-Pacific is anticipated to witness notable growth owing to rise in patient population, development of healthcare infrastructure, and increase in investments projects in the region, thus, boosting the hyperhidrosis treatment industry.
Key findings of the study
- By type, the axillary hyperhidrosis segment was the highest contributor to the market in 2021.
- By treatment, the topical treatment segment was the highest contributor to the market in 2021.
- Depending on age, the below 50 years segment was highest contributor in 2021, and is expected to continue this trend during the forecast period.
- Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Abbvie Inc.
- Avanor Healthcare Ltd.
- Brickbell Biotech, Inc.
- Dr August Wolff GmbH & Co. KG Drugs
- Eirion Therapeutics, Inc.
- Eli Lilly and Company
- Hugel, Inc.
- Kaken Pharmaceutical Co. Ltd.
- Roivant Sciences Ltd.
- Theravida, Inc.
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 281 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 575.3 million |
| Forecasted Market Value ( USD | $ 950.7 million |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
